Clinical Trials on Endometrial Clear Cell Carcinoma in New Zealand

Total 2641 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Mixed Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Auckland District Health Board
Novartis; University of Auckland, New Zealand; IGENZ, Ltd., Auckland

Unknown

1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC (DILIGENCE-1)

Clear Cell Renal Cell Carcinoma

New Zealand
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
Women's Cancer Care Associates, LLC

Completed

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Endometrial Clear Cell Carcinoma | Stage III Endometrial Carcinoma | Cervical... and other conditions

United States, Korea, Republic of, Japan, Canada
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of Nivolumab in Selected Uterine Cancer Patients

Carcinosarcoma | Leiomyosarcoma | Endometrial Carcinoma | Uterine Cancer | Clear Cell Carcinoma | Undifferentiated Sarcoma | High Grade Endometrial Stromal Sarcoma

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Nuvectis Pharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Advanced Solid Tumor | Ovarian Clear Cell Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Clear Cell Tumor | Ovarian Endometrioid Tumor | ARID1A Gene Mutation

United States, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Celldex Therapeutics

Terminated

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Kidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell Carcinoma

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus... and other conditions

United States, Canada, Hong Kong
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania
University of Pittsburgh; Rutgers Cancer Institute of New Jersey

Completed

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine... and other conditions

United States, Korea, Republic of, Canada
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell Carcinoma

United States
Australian and New Zealand Urogenital and Prostate...
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

Renal Cell Carcinoma, Clear Cell | Metastatic Kidney Cancer

Australia
Agensys, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Carcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell Histology

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Mucositis | Xerostomia | Radiation Toxicity | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma... and other conditions

United States, New Zealand
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

United States
Northwell Health
Tesaro, Inc.

Recruiting

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Endometrial Cancer | Endometrial Carcinoma | Uterine Serous Carcinoma | Cancer of the Endometrium | Papillary Serous Endometrial Carcinoma

United States
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
Eli Lilly and Company

Terminated

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

United States
Millennium Pharmaceuticals, Inc.

Completed

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

Spain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage I Renal Cell Cancer

United States

Clinical Trials on Endometrial Clear Cell Carcinoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations